Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

GE Healthcare to Build KUBio Factory for JHL Biotech in China

Published: Thursday, September 26, 2013
Last Updated: Thursday, September 26, 2013
Bookmark and Share
New factory to give JHL Biotech commercial biopharmaceutical manufacturing capabilities in Asia.

GE Healthcare Life Sciences and JHL Biotech have announced that a KUBio™ modular biopharmaceutical factory will be built in China for JHL Biotech.

The site for the new factory, which will be fully operational beginning early 2015, is the Biolake Science Park in Wuhan, China.

Worldwide demand for biopharmaceuticals, such as antibodies for the treatment of cancer and a new generation of innovative vaccines, is increasing dramatically.

KUBio is a new approach to readily establish biopharmaceutical manufacturing capacity by delivering customers a fully functional, ready-to-run bioprocessing facility in 14-18 months, which is significantly shorter than constructing a traditional facility.

Pre-designed to meet cGMP requirements, KUBio helps manufacturers, such as JHL Biotech, respond to local healthcare needs and support global customers in bringing life-saving treatments to market more quickly.

GE Healthcare’s innovative turnkey approach will involve the assembly at the JHL Biotech site in Wuhan, China of pre-made modules equipped with GE Healthcare’s world-class technologies for the start-to-finish manufacture of biopharmaceuticals.

In addition to GE project-managing the build, members of its experienced Shanghai Fast Trak team will be deployed to validate the equipment and provide training for JHL Biotech staff.

After completion, the JHL Biotech KUBio facility will have a floor space of approximately 2,400m2 and will contain a number of 2,000L single-use bioreactors.

Olivier Loeillot, General Manager of Enterprise Solutions, GE Healthcare Life Sciences, commented, “The decision of JHL Biotech’s highly experienced team to select KUBio as the basis of its commercial cGMP biopharmaceutical manufacturing capabilities in China is a fantastic endorsement of our complete, turnkey approach. We look forward to working with them to bring the facility online to serve the fast-moving biopharmaceutical industry. A diverse range of customers, including governments and pharmaceutical companies, are continuing to recognize the breadth, depth, simplicity and flexibility of what we offer with KUBio.”

Racho Jordanov, Co-founder, President and CEO of JHL Biotech, added, “In realizing our vision of making world-class biopharmaceuticals affordable and accessible to all patients, KUBio was the natural choice. Utilizing manufacturing innovations was always a key part of our strategy and GE Healthcare’s KUBio delivers the technologies we want, with the technical support and training we need.”

KUBio is the latest addition to GE Healthcare’s broad offering of world-class tools, technologies and services for the biopharmaceutical manufacturing industry, allowing customers to benefit from a wide range of solutions that can be tailored to meet specific needs, from pilot to commercial scale.

KUBio aligns with GE’s healthymagination initiative which focuses on reducing cost, increasing access and improving quality in healthcare.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

GE Healthcare Life Sciences to Open Biopharmaceutical Technology and Training Laboratory in Turkey
Supports Turkey’s ambitions to expand domestic biopharmaceutical industry. Laboratory will be a key component of GE’s new Innovation Center in Istanbul.
Friday, November 14, 2014
GE Healthcare Life Sciences Named as Finalist for Four Bioprocess Industry Awards
Awards celebrate and recognize the outstanding people, organizations and technologies.
Saturday, October 04, 2014
GE Healthcare Life Sciences to Create New US Headquarters
When fully operational, the new facility will house more than 500 highly skilled employees and bring more than 220 new jobs to Massachusetts.
Wednesday, August 20, 2014
GE Healthcare Appoints Emmanuel Ligner as General Manager
Emmanuel will oversee all worldwide commercial activities of Company's rapidly growing BioProcess business.
Friday, April 11, 2014
GE, NetBio to Validate Fully Integrated Rapid DNA system
Verification by forensic laboratories is a key step toward responsible adoption for crime laboratory and in-the-field law enforcement use.
Friday, March 21, 2014
Spectacular Images Showing Research into Cancer, Neurodegenerative Disease and Fertility
Vanessa Auld from Canada, Martin Barr from Ireland and Graham Wright from Singapore announced as the winners of the GE Healthcare 2013 Cell Imaging Competition.
Wednesday, March 12, 2014
GE Healthcare Life Sciences and Osaka University Team Up
Top four graduate students to be hosted at GE Healthcare Life Science’s Uppsala site.
Wednesday, August 21, 2013
GE Healthcare Life Sciences Completes Acquisition of Xcellerex, Inc.
Acquisition expands GE Healthcare’s offering of technologies and services for the manufacture of recombinant proteins, antibodies and vaccines.
Tuesday, May 15, 2012
Scientific News
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!